Investigational Drug Information for Belotecan
✉ Email this page to a colleague
What is the development status for investigational drug Belotecan?
Belotecan is an investigational drug.
There have been 8 clinical trials for Belotecan.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 31st 2025.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Carcinoma, Ovarian Epithelial. The leading clinical trial sponsors are Chong Kun Dang Pharmaceutical, Yonsei University, and Chonnam National University Hospital.
There are zero US patents protecting this investigational drug and zero international patents.
Summary for Belotecan
| US Patents | 1,509 |
| International Patents | 11,463 |
| US Patent Applications | 3,631 |
| WIPO Patent Applications | 1,608 |
| Japanese Patent Applications | 146 |
| Clinical Trial Progress | Phase 3 (2025-07-31) |
| Vendors | 27 |
Recent Clinical Trials for Belotecan
| Title | Sponsor | Phase |
|---|---|---|
| Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | PHASE2 |
| A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer | Gachon University Gil Medical Center | Phase 1/Phase 2 |
| Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | Chong Kun Dang Pharmaceutical | Phase 2 |
Clinical Trial Summary for Belotecan
Top disease conditions for Belotecan
Top clinical trial sponsors for Belotecan
US Patents for Belotecan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Belotecan | ⤷ Start Trial | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Formulations for tailored drug release | South Dakota Board of Regents (Pierre, SD) Sanford Health (Sioux Falls, SD) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Glutaminase inhibitors and method of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Therapeutically active compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Belotecan | ⤷ Start Trial | Aryl-cyanoguanidine compounds | Bayer Pharma Aktiengesellschaft (Berlin, DE) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Belotecan
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Belotecan | World Intellectual Property Organization (WIPO) | WO2015148714 | 2034-03-25 | ⤷ Start Trial |
| Belotecan | Australia | AU2015231053 | 2034-03-21 | ⤷ Start Trial |
| Belotecan | Brazil | BR112016021620 | 2034-03-21 | ⤷ Start Trial |
| Belotecan | Canada | CA2943339 | 2034-03-21 | ⤷ Start Trial |
| Belotecan | China | CN106231900 | 2034-03-21 | ⤷ Start Trial |
| Belotecan | Eurasian Patent Organization | EA201691896 | 2034-03-21 | ⤷ Start Trial |
| Belotecan | European Patent Office | EP3119199 | 2034-03-21 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
